JOHN R. RICHARDSON, M.D.; MORTON B. WEINSTEIN, M.D.
Fifteen patients on a program of maintenance dialysis were given courses of testosterone enanthate therapy in weekly doses of 400 to 600 mg, intramuscularly, for 5 to 44 weeks. Thirteen patients exhibited a mean increment in hematocrit (5.6%), red cell volume (353 ml), and red cell volume per kilogram body weight (4.4 ml/kg). The mean rate of plasma iron clearance increased (-36.7 min). In several individuals marked improvement in anemia occurred. Two iron-deficient patients failed to exhibit an erythropoietic response to testosterone. A satisfactory response followed iron replacement. Androgenic hormones may be useful in the treatment of patients with advanced renal failure who are adequately dialyzed, well nourished, and not iron-deficient. This treatment, in conjunction with other measures aimed toward amelioration of anemia, has eliminated transfusion requirements in most of our patients.
Learn more about subscription options.
Register Now for a free account.
RICHARDSON JR, WEINSTEIN MB. Erythropoietic Response of Dialyzed Patients to Testosterone Administration. Ann Intern Med. 1970;73:403-407. doi: 10.7326/0003-4819-73-3-403
Download citation file:
Published: Ann Intern Med. 1970;73(3):403-407.
Hematology/Oncology, Nephrology, Red Cell Disorders, Renal Replacement Therapy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only